Foghorn Therapeutics

88 articles about Foghorn Therapeutics

• Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

  9/1/2021

  Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.

• Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609

  8/23/2021

  Foghorn Therapeutics Inc., a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, announced that the first patient has been dosed in a first-in-human clinical trial of FHD-609, which is being developed as a treatment for synovial sarcoma.

• Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update

  8/10/2021

  Foghorn Therapeutics Inc. today provided a corporate update in conjunction with the Company’s From 10-Q filing for the quarter ended June 30, 2021.

• Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference

  8/3/2021

  Foghorn Therapeutics Inc. today announced that Steven Bellon, Ph.D., Senior Vice President of Drug Discovery, is scheduled to participate in a panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference, which is being held from August 10-11.

• Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021

  7/9/2021

  Foghorn Therapeutics Inc. today announced that Adrian Gottschalk, President & Chief Executive Officer, is scheduled to participate in a panel at the William Blair Biotech Focus Conference 2021, which is being held virtually from July 14-15.

• Foghorn Therapeutics to Host Research & Development Day Webinar on June 15th

  6/8/2021

  Foghorn Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced that it will host a research and development webinar on June 15th from 9:00 AM - 11:00 AM EDT.

• Foghorn Therapeutics to Present in Two Upcoming Investor Conferences - May 26, 2021

  5/26/2021

  Foghorn Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced that Adrian Gottschalk, President and Chief Executive Officer, will present at two upcoming investor conferences.

• 

  Clinical Catch-Up: May 17-21

  5/24/2021

  It was another busy week for clinical trial announcement. Here’s a look.

• Foghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286

  5/17/2021

  Foghorn Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced that the first patient has been dosed in a first-in-human clinical trial of FHD-286 in metastatic uveal melanoma.

• Foghorn Therapeutics Provides Corporate Update - May 11, 2021

  5/11/2021

  Received IND clearance for FHD-609, a targeted protein degrader, which is being developed for the treatment of synovial sarcoma

• Foghorn Therapeutics Appoints Ian Smith to its Board of Directors

  4/28/2021

  Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Ian Smith to its Board of Directors effective, April 27.

• 

  Q&A: Foghorn SVP Expounds on "Tremendous Opportunity" in Chromatin Remodeling

  4/20/2021

  BioSpace caught up Foghorn Therapeutics’ Steven Bellon, Ph.D., SVP, drug discovery, shortly before he chaired a panel on new epigenetic developments at the AACR Annual Meeting 2021.

• Foghorn Therapeutics Provides Corporate Update

  3/18/2021

  -  FHD-286 Phase 1 data anticipated as early as year-end 2021 -  FHD-609 IND submission on track for the second quarter 2021 -  Continued advancement of broad therapeutic pipeline targeting the chromatin regulatory system

• UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel at the AACR Annual Meeting 2021

  3/11/2021

  Foghorn Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced that the company will present a poster and chair a panel at the American Association for Cancer Research Annual Meeting 2021, which is being held virtually from April 10-15.

• Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021

  3/11/2021

  Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that the company will present a poster and chair a panel at the American Association for Cancer Research (AACR) Annual Meeting 2021,

• Foghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare Conference

  2/22/2021

  Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Sam Agresta, M.D., M.P.H, Chief Medical officer is scheduled to participate in a Leukemias panel discussion at the Cowen 41st Annual Healthcare Conference

• Foghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update

  12/4/2020

  Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.

• Foghorn Therapeutics Appoints Michael LaCascia as Chief Legal Officer

  11/12/2020

  Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Michael LaCascia as its Chief Legal Officer

• 

  Biopharma Money on the Move: October 21-27

  10/28/2020

  Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

• Foghorn Therapeutics Announces Pricing of Initial Public Offering

  10/23/2020

  Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of $16.00 per share